Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Moves HBV Drug into Phase I Testing


NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals announced this week that it has initiated a Phase I trial of its RNAi-based hepatitis B therapy TKM-HBV, a key milestone for the company as it prepares to merge with HBV drug firm OnCore BioPharma.

TKM-HBV comprises siRNAs targeting several sites on the HBV genome and is delivered using Tekmira's lipid nanoparticles (LNPs). In preclinical testing, the drug has been shown to trigger reductions in HBV surface antigen, a key indicator of active infection, as well as cccDNA.

According to Tekmira, the 40-subject study will examine single ascending doses of two formulations of the drug in healthy adults. For each formulation, there are five planned cohorts for a total of 20 subjects. Four subjects will be enrolled per cohort with three subjects receiving TKM-HBV, and one receiving placebo.

"Since TKM-HBV represents our most important development program, we are testing two LNP formulations — generations three and four — of the product in this study," Tekmira CEO Mark Murray said in a statement. "We expect the results to determine which product formulation we will advance into chronically infected patients later this year."

While Tekmira has a variety of different RNAi drugs under development, TKM-HBV has become its most important following the company's announcement that it would merge with OnCore later this year to become an HBV-focused company.

After the transaction is completed, Tekmira expects to have two HBV drugs, including TKM-HBV, in human testing this year, with multiple others entering the clinic in 2016. The deal was valued at $750 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.